Base de dados : LILACS
Pesquisa : D12.776.377.856 [Categoria DeCS]
Referências encontradas : 121 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 121 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Corrente, José Eduardo
Texto completo
Id: biblio-984042
Autor: Amui, Isabela de Oliveira; Tagliarini, José Vicente; Castilho, Emanuel C; Marques, Mariângela de Alencar; Kiy, Yoshio; Corrente, José Eduardo; Mazeto, Gláucia M F S.
Título: The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas / A primeira dosagem sérica de tireoglobulina estimulada pós-operatória é um fator prognóstico para os microcarcinomas da tireoide
Fonte: Braz. j. otorhinolaryngol. (Impr.);85(1):37-42, Jan.-Feb. 2019. tab, graf.
Idioma: en.
Resumo: Abstract Introduction: Endogenous thyroid-stimulating hormone-stimulated thyroglobulin collected after total thyroidectomy is a useful predictor of better prognosis in patients with differentiated thyroid carcinomas in general, but studies with microcarcinomas are scarce. Objective: To assess whether the first postoperative stimulated thyroglobulin measurement is a prognostic factor in patients with microcarcinoma. Methods: The medical data of 150 differentiated thyroid carcinoma patients were studied retrospectively, and 54 (36%) cases with microcarcinoma were selected. The first postoperative stimulated thyroglobulin (1st stimulated thyroglobulin), measured after thyroidectomy, initial presentation data, and microcarcinomas treatment were assessed regarding outcome. Worse prognosis was defined as neoplasm persistence/recurrence. Results: Persistence/recurrence occurred in 27.8% of the cases. These patients were identified according to the following parameters: receiving more than one 131iodine dose (100% vs. 0%; p < 0.0001); accumulated 131iodine dose (232.14 ± 99.09 vs. 144 ± 33.61 mCi; p < 0.0001); presented active disease in the last assessment (53.3% vs. 0%; p < 0.0001); follow-up time (103.07 ± 61.27 vs. 66.85 ± 70.14 months; p = 0.019); and 1st stimulated thyroglobulin (19.01 ± 44.18 vs. 2.19 ± 2.54 ng/dL; p < 0.0001). After multivariate logistic regression, only the 1stSTg [odds ratio = 1.242; 95% confidence interval: 1.022-1.509; p = 0.029] and follow-up time (odds ratio = 1.027; 95% confidence interval: 1.007-1.048; p = 0.007) were independent predictors of risk of persistence/recurrence. The cutoff point of 1.6 ng/dL for the 1st stimulated thyroglobulin was significantly associated with disease persistence/recurrence [area under the curve = 0.713 (p = 0.019)]. Conclusion: The first stimulated thyroglobulin predicted disease persistence/recurrence in patients with microcarcinoma.

Resumo Introdução: A tireoglobulina estimulada pelo hormônio tireoestimulante endógeno coletada após tireoidectomia total é um preditor útil de melhor prognóstico em pacientes com carcinomas diferenciados de tireoide em geral, mas os estudos com microcarcinomas são escassos. Objetivo: Avaliar se a primeira medida pós-operatória de tireoglobulina estimulada é um fator prognóstico em pacientes com microcarcinoma. Método: Os dados clínicos de 150 pacientes com carcinoma diferenciado de tireoide foram estudados retrospectivamente e 54 (36%) casos com microcarcinoma foram selecionados. A primeira dosagem de tireoglobulina estimulada (1a TgE) pós-operatória, medida após a tireoidectomia, os dados da apresentação inicial e tratamento do microcarcinoma foram avaliados quanto ao resultado. O pior prognóstico foi definido como a persistência/recorrência da neoplasia. Resultados: A persistência/recorrência ocorreu em 27,8% dos casos. Esses pacientes foram identificados de acordo com os seguintes parâmetros: receberam mais de uma dose de iodo131 (100% vs. 0%; p < 0,0001); dose acumulada de iodo131 (232,14 ± 99,09 vs. 144 ± 33,61 mCi; p < 0,0001); apresentou doença ativa na última avaliação (53,3% vs. 0%; p < 0,0001); tempo de seguimento (103,07 ± 61,27 vs. 66,85 ± 70,14 meses; p = 0,019); e 1ªTgE (19,01 ± 44,18 vs. 2,19 ± 2,54 ng/dL; p < 0,0001). Após a regressão logística multivariada, apenas a 1ª TgE [odds ratio = 1.242; intervalo de confiança de 95%: 1,022-1,509; p = 0,029] e tempo de seguimento (odds ratio = 1,027; intervalo de confiança de 95%: 1,007-1,048; p = 0,007) foram preditores independentes de risco de persistência/recorrência. O ponto de corte de 1,6 ng/dL para a 1a TgE foi significativamente associado à persistência/recidiva da doença [área abaixo da curva = 0,713 (p = 0,019)]. Conclusão: A 1ª dosagem sérica de tireoglobulina estimulada previu a persistência/recorrência da doença em pacientes com microcarcinoma.
Descritores: Tireoglobulina/sangue
Neoplasias da Glândula Tireoide/sangue
Carcinoma/sangue
-Período Pós-Operatório
Prognóstico
Valores de Referência
Tireoidectomia/métodos
Neoplasias da Glândula Tireoide/cirurgia
Neoplasias da Glândula Tireoide/patologia
Carcinoma/cirurgia
Carcinoma/patologia
Biomarcadores Tumorais/sangue
Modelos Logísticos
Valor Preditivo dos Testes
Reprodutibilidade dos Testes
Estudos Retrospectivos
Curva ROC
Recidiva Local de Neoplasia/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  2 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-792951
Autor: Morosán, Yanina Jimena; Parisi, Carina; Urrutia, María Agustina; Rosmarin, Melanie; Schnitman, Marta; Serrano, Leonardo; Luciani, Wilfrido; Faingold, Cristina; Pitoia, Fabián; Brenta, Gabriela.
Título: Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma
Fonte: Arch. endocrinol. metab. (Online);60(4):348-354, Aug. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective The reclassification of the risk according to the response to the initial treatment makes the treatment of differentiated thyroid cancer (DTC) vary in each individual. As the influence of age on this diagnostic strategy is unknown, we have decided to assess it in adults who are over 60 years of age. Subjects and methods Ninety patients with DTC above 60 years old were enrolled, with total thyroidectomy plus radioiodine ablation, negative anti-thyroglobulin antibodies, follow-up ≥ 2 years and with clinical and pathological information to classify the risk of recurrence according to ATA (American Thyroid Association) and reclassify based on the response to initial therapy according to MSKCC (Memorial Sloan Kettering Cancer Center). The structural persistence at the end of the follow-up was the gold standard of our analysis. Results The structural persistence in ATA low, intermediate and high risk categories was 0, 38, and 100%, respectively. In the intermediate group, none of those with an excellent response to the initial treatment showed structural persistence, whereas 39% of those with an incomplete/indeterminate response showed structural persistence (p < 0.01). Conclusions The re-stratification according to the response to the initial treatment in patients over 60 years of age with an ATA intermediate risk of recurrence allowed for the distinction of disease-free patients at the end of the follow-up from those with structural persistence and a worse clinical progression.
Descritores: Neoplasias da Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/terapia
Carcinoma/patologia
Carcinoma/terapia
Medição de Risco/métodos
Recidiva Local de Neoplasia
-Tireoglobulina/sangue
Tireoidectomia
Estudos Retrospectivos
Fatores de Risco
Seguimentos
Fatores Etários
Resultado do Tratamento
Intervalo Livre de Doença
Radioisótopos do Iodo/uso terapêutico
Estadiamento de Neoplasias
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  3 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838426
Autor: Martins-Costa, M Cecilia; Maciel, Rui M B; Kasamatsu, Teresa S; Nakabashi, Claudia C D; Camacho, Cleber P; Crispim, Felipe; Ikejiri, Elza S; Mamone, M Conceição O; Andreoni, Danielle M; Biscolla, Rosa Paula M.
Título: Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma
Fonte: Arch. endocrinol. metab. (Online);61(2):108-114, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Projeto: São Paulo State Research Foundation; . Brazilian Ministry of Health.
Resumo: ABSTRACT Objectives The presence of thyroglobulin (Tg) in needle washouts of fine needle aspiration biopsy (Tg-FNAB) in neck lymph nodes (LNs) suspected of metastasis has become a cornerstone in the follow-up of patients with papillary thyroid carcinoma (PTC). However, there are limited data regarding the measurement of anti-Tg antibodies in these washouts (TgAb-FNAB), and it is not clear whether these antibodies interfere with the assessment of Tg-FNAB or whether there are other factors that would more consistently justify the finding of low Tg-FNAB in metastatic LNs. Materials and methods We investigated 232 FNAB samples obtained from suspicious neck LNs of 144 PTC patients. These samples were divided according to the patient’s serum TgAb status: sTgAb- (n = 203 samples) and sTgAb+ (n = 29). The TgAb-FNAB levels were measured using two different assays. Tg-FNAB was also measured using two assays when low levels (< 10 ng/mL) were identified in the first assay of the metastatic LNs from the sTgAb+ samples. Results The TgAb-FNAB results were negative in both assays in all samples. Low levels of Tg-FNAB were identified in 11/16 of the metastatic LNs of the sTgAb+ patients and 16/63 of the sTgAb- patients (p < 0.05) using assay 1. The measurement of the Tg-FNAB levels using assay 2 indicated additional metastases in 5 LNs of the sTgAb+ patients. Conclusions Factors other than the presence of TgAb-FNAB may contribute to the higher number of metastatic LNs with undetectable Tg-FNAB in the sTgAb+ group. In addition, the measurement of Tg-FNAB using different assays was useful to enhance the diagnosis of metastatic LNs, particularly when cytological and Tg-FNAB results are discordant.
Descritores: Autoanticorpos/sangue
Tireoglobulina/sangue
Neoplasias da Glândula Tireoide/sangue
Carcinoma/sangue
Linfonodos/imunologia
-Valores de Referência
Carcinoma/imunologia
Carcinoma/patologia
Carcinoma Papilar
Fluorimunoensaio/métodos
Valor Preditivo dos Testes
Biópsia por Agulha Fina/instrumentação
Biópsia por Agulha Fina/métodos
Linfonodos/patologia
Metástase Linfática/imunologia
Metástase Linfática/patologia
Pescoço
Limites: Humanos
Responsável: BR1.1 - BIREME


  4 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838427
Autor: Vaisman, Fernanda.
Título: Serum positive thyroglobulin antibodies: an old problem with new questions
Fonte: Arch. endocrinol. metab. (Online);61(2):103-104, Mar.-Apr. 2017.
Idioma: en.
Descritores: Autoanticorpos/sangue
Tireoglobulina/sangue
Limites: Humanos
Tipo de Publ: Comentário
Editorial
Responsável: BR1.1 - BIREME


  5 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887617
Autor: Bandeira, Leonardo; Padovani, Rosália do Prado; Ticly, Ana Luiza; Cury, Adriano Namo; Scalissi, Nilza Maria; Marone, Marília Martins Silveira; Ferraz, Carolina.
Título: Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer
Fonte: Arch. endocrinol. metab. (Online);61(6):590-599, Dec. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: We sought to assess the relationship between stimulated thyroglobulin (sTg) before radioactive iodine therapy (RIT), and the dynamic risk stratification 1 year after treatment, and to establish the utility of the sTg as a predictor of response to therapy in these patients. A retrospective chart review of patients with differentiated thyroid cancer (DTC) who underwent RIT after surgery and were followed for at least 1 year, was carried out. Subjects and methods: Patients were classified according to the dynamic risk stratification 1 year after initial treatment. The sTg values before RIT were compared among the groups. ROC curve analysis was performed. Results: Fifty-six patients were enrolled (mean age 44.7 ± 14.4 years, 80.7% had papillary carcinoma). Patients with excellent response had sTg = 2.1 ± 3.3 ng/mL, those with indeterminate response had sTg = 8.2 ± 9.2 ng/mL and those with incomplete response had sTg = 22.4 ± 28.3 ng/mL before RIT (p = 0.01). There was a difference in sTg between excellent and incomplete response groups (p = 0.009) while no difference was found between indeterminate and either excellent or incomplete groups. The ROC curve showed an area under the curve of 0.779 assuming a sTg value of 3.75 ng/mL. Conclusion: Our study results suggest that the higher the sTg before RIT, the greater the likelihood of an incomplete response to initial treatment. A sTg cut-off of 3.75 ng/mL was found to be a good predictor of response to initial treatment in patients with DTC.
Descritores: Tireoglobulina/sangue
Neoplasias da Glândula Tireoide/radioterapia
Carcinoma Papilar/radioterapia
Adenocarcinoma Folicular/radioterapia
Radioisótopos do Iodo/uso terapêutico
-Prognóstico
Fatores de Tempo
Neoplasias da Glândula Tireoide/sangue
Carcinoma Papilar/sangue
Biomarcadores Tumorais/sangue
Estudos Retrospectivos
Curva ROC
Resultado do Tratamento
Adenocarcinoma Folicular/sangue
Medição de Risco
Estadiamento de Neoplasias
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  6 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-731750
Autor: Llamas-Olier, Augusto; Martínez, María Cristina; De los Reyes, Amelia; Cadena, Enrique; Rojas, Leonardo; Varela, Humberto; Marti, Alejandro; Calderón, Álvaro; Angarita, Emperatriz.
Título: La Terapia empírica del cáncer de tiroides con I-131 como estrategia diagnóstica para identificar lesiones ocultas en pacientes con tiroglobulina elevada sin enfermedad estructural identificable / Empirical radioiodine therapy as diagnostic strategy to identify occult lesions in thyroid cancer patients with elevated thyroglobulin levels but no structurally identifiable disease
Fonte: Rev. colomb. cancerol;18(4):157-165, oct.-dic. 2014. ilus, tab.
Idioma: es.
Resumo: Objetivos: establecer la prevalencia de resultados positivos en el rastreo posterapia empírica; determinar valores de corte para tiroglobulina estimulada y suprimida que predijeron el resultado del rastreo posterapia empírica y describir factores clínicos e histopatológicos asociados con rastreos positivos. Métodos: se revisaron historias clínicas de pacientes, del Instituto Nacional de Cancerología (INC) entre 2003 y 2009, con cáncer diferenciado de tiroides y que tuvieron una tiroglobulina estimulada ≥ 10 ng/ml en ausencia de enfermedad estructural identificable por ecografía de cuello y por otras imágenes diagnósticas obtenidas a discreción de los médicos tratantes. Se les practicó un rastreo posterapia después de recibir 100-200 mCi de I-131. Resultados: se incluyeron 40 pacientes (34 mujeres) con cáncer diferenciado de tiroides, de 14 a 74 años de edad, la mayoría con invasión local o compromiso de ganglios cervicales. El rastreo posterapia fue positivo en 24 pacientes. Los valores de corte de tiroglobulina suprimida y estimulada que mejor predijeron los resultados del rastreo posterapia fueron 1,89 ng/ml y 25 ng/ml, respectivamente. Factores como edad ≥ 45 años, sexo masculino, variantes agresivas y otras variables de mal pronóstico (tumor > 4 cm, primera cirugía extrainstitucional, tiroglobulina postoperatoria > 30 ng/ml y respuesta estructural incompleta (80%)) fueron más frecuentes en los pacientes con rastreo positivo. Conclusiones: el rastreo posterapia empírica con I-131 es una estrategia diagnóstica que provee información localizadora, metabólica y pronóstica en la mayoría de los pacientes. © 2014 Instituto Nacional de Cancerología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Objectives: a) To establish the prevalence of positive post-therapeutic I-131 whole-body scan (PWBS) results in patients with elevated thyroglobulin (Tg) levels and with no structurally identifiable disease; b) to calculate stimulated and suppressed Tg cut-off values with the highest accuracy using ROC analyses; c) to describe positive PWBS-related clinical and histopathology factors. Methods: A retrospective assessment is presented of PWBS results in 40 patients (34 female) between 14 and 74 years of age with differentiated thyroid cancer (DTC) who were treated with empirical radioiodine therapy at the Instituto Nacional de Cancerología between 2003 and 2009, and with a stimulated Tg ≥ 10 ng/ml with no structurally identifiable disease. Results: PWBS revealed a pathological uptake in 24 (60%) patients. The highest diagnostic accuracies of serum Tg for abnormal I-131 uptake in PWBS were 1.89 ng/ml for suppressed Tg and 25 ng/ml for stimulated Tg. Factors such as age ≥ 45 years, aggressive variants, and other poor outcome predictors, tumor size > 4 cm, extra-institutional first surgery, postoperative thyroglobulin >30 ng/ml and structurally incomplete tumor response to initial treatment, were more frequently related to positive PWBS. Conclusion: PWBS is a diagnostic strategy that provides localizing, metabolic and prognostic information in most patients with elevated Tg levels and with no structurally identifiable disease.
Descritores: Terapêutica
Neoplasias da Glândula Tireoide
-Tireoglobulina
Radioisótopos do Iodo
Métodos
Limites: Humanos
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Relatório Técnico
Responsável: CO40.1 - Biblioteca Médica


  7 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-177910
Autor: Medoza, Germán; Cano, Roque; Morales, Rosanna; Postigo, Juan; Farfán, Julio César; Huanca, María.
Título: Tiroglobulina sérica y rastreo tiroideo en pacientes operados por cáncer diferenciado de tiroides / Serum thyroglobulin determination and total body scan in patients with total thyroidectomy for differentiated thyroid cancer
Fonte: Acta cancerol;24(4):19-23, dic. 1994. tab.
Idioma: es.
Resumo: El carcinoma de tiroides es el tumor maligno más frecuente en la patología endocrina. En nuestro medio tiene una incidencia de 1,87 casos por cada cien mil habitantes. La tiroglobulina es una iodogliproteína que se utiliza en el seguimiento de pacientes portadores de cáncer tiroideo diferenciado. El rastreo tiroideo con iodo 131 es un procedimiento con demostrada utilidad en la detección de metástasis funcionantes causadas por esta patología. Se reporta la concordancia entre estos dos métodos en 22 pacientes derivados al Centro de Medicina Nuclear y procedentes del Departamento de Cabeza y Cuello del INEN, los cuales habían sido sometidos a tiroidectomía total y recibido dosis ablativa de iodo 131; posteriormente fueran sometidos a rastreo corporal total y determinada la concentración de tiroglobulina sérica. Catorce de los pacientes fueron mujeres y un número igual fueron calificados como portadores de cáncer de alto riesgo. Se concluye que para la población estudiada existió excelente correlación entre los dos métodos y que para el futuro se utilizará a 6,5 ng/ml como punto de corte en la determinación de tiroglobulina sérica
Descritores: Tireoglobulina
Neoplasias da Glândula Tireoide/complicações
Neoplasias da Glândula Tireoide/diagnóstico
-Cintilografia/instrumentação
Cintilografia
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  8 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: lil-575501
Autor: Rodríguez Gonzàlez, Julio César; Turcios Tristà, Silvia Elena.
Título: Limitaciones técnicas de los métodos para cuantificar tiroglobulina sérica y su repercusión clínica: [revisión] / Technical limitations of methods to quantify the serum thyroglobulin and its clinical repercussion: [review]
Fonte: Rev. cuba. endocrinol;21(1), ene.-abr. 2010.
Idioma: es.
Resumo: La determinación de tiroglobulina sérica se emplea, sobre todo, como marcador tumoral en el seguimiento posoperatorio de pacientes con cáncer diferenciado del tiroides. Lamentablemente, los métodos de tiroglobulina sérica presentan gran variabilidad en sus cualidades analíticas y padecen problemas técnicos que repercuten sobre la utilidad clínica de esta prueba. Para cuantificar tiroglobulina sérica se emplean 2 tecnologías diferentes: los iniciales radioinmunoensayos competitivos y los mßs recientes métodos inmunométricos no competitivos. Estos últimos son más propensos a sufrir las interferencias provocadas por la presencia de autoanticuerpos tiroglobulina y anticuerpos heterofílicos, a pesar de brindar los beneficios técnicos relativos al uso de reactivos no isotópicos, menor volumen de muestra, tiempos de incubación más cortos, así como mejor sensibilidad y facilidad de automatización. Resulta esencial que los clínicos conozcan y comprendan las limitaciones técnicas inherentes a la determinación de tiroglobulina sérica y su repercusión sobre la utilidad clínica de esta, con la finalidad de hacer un uso efectivo y eficiente de esta prueba en el seguimiento posoperatorio de pacientes con cáncer diferenciado del tiroides(AU)

The serum thyroglobulin assessment is used mainly as tumor marker during the postoperative follow-up of patients presenting with thyroid differentiated cancer. Progressively, the serum thyroglobulin methods have much variability in its analytical qualities and also have technical problems affecting on the technical usefulness of this test. To quantify the serum thyroglobulin we used two different technologies: the initial competitive radioimmunoassays and the most recent non competitive inmunometrical methods. These latter are more prone to have interferences provoked by presence of thyroglobulin antibodies and heterophilic antibodies despite to offer technical beneficial relative to use of non-isotopic reagents, a lower sample volume, shorter incubation times, as well as a better sensitivity and feasibility of automation. It is essential that clinicians know and understand the technical limitations inherent of serum thyroglobulin assessment and its repercussion on its clinical usefulness to an effective and efficient use of this test during the postoperative follow-up of patients presenting thyroid differential cancer(AU)
Descritores: Tireoglobulina/administração & dosagem
Neoplasias da Glândula Tireoide/diagnóstico
Tireotropina/análise
Limites: Humanos
Responsável: CU1.1 - Biblioteca Médica Nacional


  9 / 121 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: lil-663849
Autor: Marrero Rodríguez, María Teresa.
Título: Utilidad clínica de las pruebas hormonales e inmunológicas en la evaluación de las enfermedades del tiroides / Clinical usefulness of hormonal and immunological tests for the evaluation of thyroid diseases
Fonte: Rev. cuba. endocrinol;23(3):248-255, sep.-dic. 2012.
Idioma: es.
Resumo: Las enfermedades tiroideas son un importante problema de salud que afecta a un gran porcentaje de la población. Las pruebas bioquímicas constituyen el pilar fundamental para su diagnóstico y seguimiento. El desarrollo de ensayos de segunda y tercera generación ha supuesto un gran avance en el diagnóstico de estas enfermedades. El texto incluye los ensayos utilizados para diagnosticar y tratar las diferentes enfermedades tiroideas, provee información bioquímica y clínica actualizada contenida en secciones referidas a la utilidad clínica de las determinaciones de hormonas tiroideas totales y libres, anticuerpos antitiroideos, tirotropina humana y tiroglobulina, de manera que pueda ofrecer, tanto al laboratorio como al médico, un panorama general de la utilidad y la capacidad actual de estas pruebas(AU)

Thyroid diseases are a significant health problem affecting a high percentage of the population. The biochemical tests are the fundamental pillar for diagnosis and follow-up. The development of second and third-generation assays has represented a great advance in diagnosing these diseases. The text covers the tests to diagnose and treat a number of thyroid diseases, and provides the reader with updated biochemical and clinical information in sections about the clinical usefulness of total and free thyroid hormone determinations, antithyroid antibodies, human thyrotropin and thyroglobulin. In this way, it can offer both the lab and the physician a general overview of the usefulness and the current capability of these tests(AU)
Descritores: Doenças da Glândula Tireoide/diagnóstico
Hormônios Tireóideos/imunologia
Doenças da Glândula Tireoide/terapia
Tireoglobulina
Tireotropina
-Sensibilidade e Especificidade
Limites: Humanos
Responsável: CU1.1 - Biblioteca Médica Nacional


  10 / 121 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-632998
Autor: Bergoglio, Liliana M; Mestman, Jorge H.
Título: Guía de consenso para el diagnóstico y seguimiento de la enfermedad tiroidea: Parte III / Consensus guide for the diagnosis and monitoring of thyroid disease * - Part III
Fonte: Acta bioquím. clín. latinoam;41(1):87-119, ene.-mar. 2007. graf, tab.
Idioma: es.
Descritores: Doenças da Glândula Tireoide/tratamento farmacológico
Doenças da Glândula Tireoide/diagnóstico por imagem
Glândula Tireoide
-Pentagastrina
Autoanticorpos
Autoanticorpos/análise
Tireoglobulina
Calcitonina
Carcinoma
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde